Rapport Therapeutics, Inc. Common StockRAPPNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank18
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Latest
-41.43%
↓ 110% vs avg
Percentile
P18
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
-19.75%
Historical baseline
PeriodValue
Q4 2025-41.43%
Q3 202530.34%
Q2 2025-23.88%
Q1 2025-40.09%
Q4 202412.00%
Q3 2024-0.39%
Q2 20247.17%
Q1 2024-70.08%
Q4 2023-90.95%
Q3 202317.81%
Q2 2023-37.45%
Q1 20230.00%